1. Home
  2. SO vs INM Comparison

SO vs INM Comparison

Compare SO & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Company (The)

SO

Southern Company (The)

HOLD

Current Price

$94.63

Market Cap

99.2B

Sector

Utilities

ML Signal

HOLD

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$0.88

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SO
INM
Founded
1946
1981
Country
United States
Canada
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.2B
3.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SO
INM
Price
$94.63
$0.88
Analyst Decision
Hold
Analyst Count
16
0
Target Price
$94.03
N/A
AVG Volume (30 Days)
6.3M
64.2K
Earning Date
02-19-2026
02-05-2026
Dividend Yield
3.20%
N/A
EPS Growth
N/A
N/A
EPS
4.02
N/A
Revenue
$28,913,000,000.00
$4,506,597.00
Revenue This Year
$10.02
N/A
Revenue Next Year
$5.19
N/A
P/E Ratio
$23.01
N/A
Revenue Growth
9.40
N/A
52 Week Low
$83.09
$0.89
52 Week High
$100.84
$7.98

Technical Indicators

Market Signals
Indicator
SO
INM
Relative Strength Index (RSI) 66.74 32.56
Support Level $88.84 $0.90
Resistance Level $93.26 $1.09
Average True Range (ATR) 1.50 0.06
MACD 0.32 -0.01
Stochastic Oscillator 89.79 0.00

Price Performance

Historical Comparison
SO
INM

About SO Southern Company (The)

Southern is one of the largest utilities in the US. The company serves 9 million customers with vertically integrated electric utilities in three states and natural gas distribution utilities in four states. It owns 44 gigawatts of rate-regulated generating capacity, primarily for serving customers in Georgia, Alabama, and Mississippi. Subsidiary Southern Power owns 13 gigawatts of natural gas generation and renewable energy across the US and sells the electricity primarily under long-term contracts.

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Share on Social Networks: